|Bid||79.10 x 800|
|Ask||87.68 x 800|
|Day's Range||86.04 - 87.84|
|52 Week Range||42.62 - 88.60|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CNBC’s Erin Black, who has Type 1 Diabetes, puts the Dexcom G6 to the test to see if it’s as accurate as previous glucose monitors that require a finger prick and blood.
Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.
On a per-share basis, the San Diego-based company said it had a loss of 28 cents. Losses, adjusted for non-recurring gains, came to 32 cents per share. The results met Wall Street expectations. The average ...
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a pharmacy operator's stock.
The U.S. Food and Drug Administration on Tuesday approved DexCom Inc's monitoring system to check blood sugar levels in children and adults suffering from diabetes, which can be used along with devices such as insulin pumps. This is the first glucose monitoring system permitted by the agency that can be used with other compatible medical devices, the FDA said. A previous version of DexCom's monitoring system had received FDA approval in 2016 but was not designed to be used with other devices.
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.
The San Diego-based company said it had a loss of 11 cents per share. Earnings, adjusted for pretax expenses, were 10 cents per share. The results beat Wall Street expectations. The average estimate of ...
DexCom (NASDAQ: DXCM ) will be releasing its next round of earnings Tuesday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Based on ...
The bulls that were plowing into Fitbit Inc (NYSE:FIT) headed into Thursday’s post-close earnings report are likely regretting that decision now. After gaining 5% during regular trading hours, Fitbit stock is now tanking the tune of 13% in pre-market action when disappointing results were underscored by even more disappointing guidance. No. If nothing else, Fitbit is a powerful brand name that will always be able to leveraged somehow.
DexCom Inc (NASDAQ:DXCM), a medical equipment company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...
Fitbit shares dropped 13% in after-hours trading on Monday after the company missed on earnings and revenue for its fiscal fourth quarter.
The Soros Fund Management opened up smallish positions in the mid-cap biotechs DexCom and AnaptysBio in the most recent quarter.
Diverse product portfolio and strong veterinary business prospects to drive Patterson Companies (PDCO) in Q3. However, sluggishness in the Dental-Supply segment is a woe.